Takara Bio establish technology to manufacture CAR-T cells within 2 days

https://bio.nikkeibp.co.jp/atcl/news/p1/23/09/05/11051/

Takara Bio has announced that it has established a technology to rapidly produce chimeric antigen receptor T cells (CAR-T cells). By shortening the culture period to two days, it is possible to produce CAR-T cells with higher cytotoxic activity than usual, and the company plans to utilize this in its CDMO business.┬áThe company’s CDMO business has strengths in manufacturing cultured cells, mRNA drug substances, viral vectors, etc. for cell medicine and gene therapy. The company also undertakes contract manufacturing of GMP/GCTP grade CAR-T cells, and has recently developed technology to reduce manufacturing costs and improve the therapeutic efficacy of CAR-T preparations.

Takara Bio establish technology to manufacture CAR-T cells within 2 days
Scroll to top